Nova Biomedical Continues International Expansion with New Subsidiary in Australia


FOR IMMEDIATE RELEASE: May 24, 2024
Contact: info@novabiomedical.com

Waltham, MA - Nova Biomedical is pleased to announce the opening of a new sales, service, and distribution subsidiary in Australia. The new facility demonstrates Nova’s continued growth and the expansion of Nova’s biotechnology and clinical products in Australia, New Zealand, and the surrounding South Pacific countries.

Nova’s newest international subsidiary, Nova ANZ Pty, Ltd., welcomes a new team from Australia and New Zealand representing its 11th subsidiary. With Headquarters in Sydney, Australia, and warehouses in Sydney and Auckland, New Zealand, Nova expands its global footprint and increases its support and dedication to healthcare and patients across the southern hemisphere.

With the new subsidiary, Nova will directly sell and support the highly successful BioProfile FLEX2 series of cell culture analyzers, as well as the company’s critical care Stat Profile Prime whole blood analyzers and well-established StatStrip® and StatSensor® line of handheld, point-of-care meters and test strips that provide rapid glucose/ketone, lactate, creatinine, and hemoglobin/hematocrit results at the bedside to support clinical decision making.

The Stat Profile Prime series of blood gas analyzers offer a comprehensive testing menu of up to 22 measured tests, including blood gases, electrolytes, metabolites, hematology, and CO-Oximetry, along with an estimated plasma volume calculation. The Prime series integrates maintenance-free cartridge technology for sensors and reagents with new, maintenance-free, whole-blood CO-Oximetry.

The new subsidiary will also promote the recently launched Allegro capillary blood testing system, which is designed to enable improved management of chronic disease in primary care settings, clinics, and pharmacies. This system offers an extensive test menu, including HbA1c, full lipid panel, urine albumin/creatinine, PT/INR, CRP, glucose, and creatinine/eGFR.

“Nova’s highly successful StatStrip product has a long history in Australia and commands a dominant market share in Australia’s main state, New South Wales, thanks to the dedication of the previous distributor team and their “Selling with Science” clinical focus on patient care. The excitement will grow this year as we plan to launch Nova’s Stat Profile Prime critical care analyzers and a wider portfolio of newer POC products into the Australian market.” said Ben Kennedy, Nova’s Sr Director of International Sales.

 

 

About Nova Biomedical
Incorporated in 1976 and based in Waltham, MA, Nova Biomedical is a world leader in the development and manufacturing of whole blood, point-of-care and critical care analyzers, as well as instruments for cell culture monitoring in the biotechnology market. Nova uses biosensor technology in products ranging from handheld meters for glucose self- and point-of-care testing to critical care whole blood analyzers designed for stat measurement of over 24 analytes. Nova’s BioProfile line has pioneered comprehensive cell culture testing, providing over 20 critical cell culture tests for a broad range of cell culture applications. Nova employs over 1,500 people worldwide and has wholly owned subsidiaries located in Australia, Benelux, Brazil, Canada France, Germany, Great Britain, Italy, Japan, Spain, and Switzerland. Certified by the International Organization for Standardization, Nova has manufacturing operations located in the U.S. and Taiwan.
www.novabiomedical.com